{"id":"cyclasol-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or burning"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye discomfort"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine A is a calcineurin inhibitor that blocks T-cell activation and reduces pro-inflammatory cytokine production in ocular tissues. By suppressing the immune-mediated inflammation characteristic of dry eye disease, it helps restore tear film stability and reduce ocular surface damage. The CyclASol formulation uses a proprietary submicron emulsion technology to enhance corneal penetration and bioavailability.","oneSentence":"CyclASol is a cyclosporine A ophthalmic emulsion that suppresses local immune responses in the eye to reduce inflammation and improve tear production in dry eye disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:40.497Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"}]},"trialDetails":[{"nctId":"NCT04523142","phase":"PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2021-01-04","conditions":"Dry Eye Disease (DED)","enrollment":202},{"nctId":"NCT04523129","phase":"PHASE3","title":"ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2020-12-05","conditions":"Dry Eye Disease","enrollment":834},{"nctId":"NCT03292809","phase":"PHASE2, PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2017-10-19","conditions":"Dry Eye Disease","enrollment":328},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207},{"nctId":"NCT02113293","phase":"PHASE1","title":"CyclASol® Phase 1 Study","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2014-03","conditions":"Healthy","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CyclASol Ophthalmic Solution","genericName":"CyclASol Ophthalmic Solution","companyName":"Novaliq GmbH","companyId":"novaliq-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CyclASol is a cyclosporine A ophthalmic emulsion that suppresses local immune responses in the eye to reduce inflammation and improve tear production in dry eye disease. Used for Dry eye disease (keratoconjunctivitis sicca).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}